论文部分内容阅读
目的:探讨真核细胞翻译起始因子eIF-4A在卵巢上皮性癌组织中的表达及其临床意义。方法:选取青岛大学医学院附属医院妇科2008-01-01-2012-12-31住院病例。应用免疫组织化学方法测定41例卵巢上皮性癌组织、23例交界性卵巢上皮性肿瘤组织、25例良性卵巢上皮性肿瘤组织及30例正常卵巢组织中eIF-4A蛋白的表达情况。结果:eIF-4A蛋白在正常卵巢组织(3.33%)和卵巢交界性肿瘤组织(60.87%)中阳性表达率差异有统计学意义,z=4.607,P<0.001;在卵巢良性肿瘤组织(12.00%)及卵巢交界性肿瘤组织中的阳性表达率差异有统计学意义,z=3.638,P<0.001;在卵巢交界性肿瘤组织和卵巢上皮性癌组织(87.80%)中阳性表达率差异有统计学意义,z=2.399,P=0.016。卵巢良性肿瘤组织和正常卵巢组织中eIF-4A蛋白的表达差异无统计学意义,z=1.239,P=0.215。eIF-4A蛋白在卵巢上皮性癌组织中的阳性表达与FIGO手术病理分期(χ2=7.080,P=0.020)、组织分级(P=0.002)及是否有淋巴结转移(P=0.008)呈明显的相关性;与患者的年龄(χ2=0.035,P=1.00)及卵巢上皮癌的病理类型(χ2=0.093,P=1.00)无明显的相关性。结论:eIF-4A可能参与卵巢上皮性癌的发生、发展并参与淋巴结转移过程,eIF-4A蛋白可能成为治疗卵巢上皮性癌的一个潜在的分子靶点。
Objective: To investigate the expression of eIF-4A, an eukaryotic cell translation initiation factor, in epithelial ovarian cancer and its clinical significance. Methods: Select the hospital of Qingdao University Medical College gynecology 2008-01-01-2012-12-31 hospitalized cases. Immunohistochemistry was used to determine the expression of eIF-4A protein in 41 cases of epithelial ovarian cancer, 23 cases of borderline ovarian epithelial tumor, 25 cases of benign ovarian epithelial tumor and 30 cases of normal ovarian tissue. Results: The positive rate of eIF-4A protein in normal ovarian tissue (3.33%) and borderline ovarian tumor (60.87%) was significantly different, z = 4.607, P <0.001; ) And ovarian borderline tumor tissues, the difference was statistically significant (z = 3.638, P <0.001). There was a statistically significant difference in the positive expression rates between ovarian borderline tumor tissues and ovarian epithelial carcinoma tissues (87.80%) Meaning, z = 2.399, P = 0.016. There was no significant difference in the expression of eIF-4A protein between benign ovarian tumor tissue and normal ovarian tissue, z = 1.239, P = 0.215. The positive expression of eIF-4A protein in epithelial ovarian cancer was significantly correlated with the pathological stage of FIGO (χ2 = 7.080, P = 0.020), histological grade (P = 0.002) and lymph node metastasis (Χ2 = 0.035, P = 1.00) and the pathological type (χ2 = 0.093, P = 1.00) of ovarian epithelial carcinoma patients. Conclusion: eIF-4A may be involved in the development of epithelial ovarian cancer and its involvement in lymph node metastasis. EIF-4A protein may be a potential molecular target for the treatment of epithelial ovarian cancer.